Own development and qualification platform for physicians, managers, and technicians.
A total of 12 annual medical symposia (Blood Boards) with technical classes on relevant subjects of Transfusion Medicine and Cell Therapy.
Own development and qualification platform for physicians, managers, and technicians.
A total of 12 annual medical symposia (Blood Boards) with technical classes on relevant subjects of Transfusion Medicine and Cell Therapy.
Extensive training programs for professionals from partner hospitals with a focus on important blood therapy topics:
Continuous investment in training and development programs for employees, as well as for the teams allocated to partner hospitals.
We hold on average 50 annual training hours per employee. That number is 50% higher than the average of other institutions in the national healthcare industry.
Over 140 scientific papers published in national and international conferences.
An important observational study published by the international journal Vox Sanguinis, a journal edited by the ISBT (International Society for Blood Transfusion), had the collaboration of hematologists who are part of the renowned clinical staff of the GSH Group. By analyzing the medical records of patients diagnosed with COVID-19, the group described the transfusion needs, characteristics and clinical outcomes of 3,014 patients in 16 hospitals located in 6 Brazilian states. The knowledge of the transfusion profile of these patients allowed us to improve strategies for the maintenance of blood supplies in hospitals during the pandemic and to reinforce our commitment to significantly contribute to the advancement of worldwide research on COVID-19.
The GSH Group, in partnership with IDOR (Instituto D’Or de Pesquisa e Ensino) and HCor (Hospital do Coração), conducts research, authorized by CONEP, with the plasma of individuals who have already tested positive for the coronavirus. In this study, people who are infected and have stopped presenting symptoms in the last 30 days donate blood plasma to be administered to patients in advanced stages of COVID-19. Collection and storage are carried out by the GSH Group, and treatment is administered by IDOR and HCOR.
Research carried out by our medical vice president – Dr. Sergio Vieira, in partnership with physicians at HCor, on intraoperative blood recovery presents the rational use of blood.
The model of care safety adopted by the GSH Group is comprised of a system for reading individual bar codes on bracelets by a computerized system. The objective is to improve patient safety, minimizing errors and obtaining traceability and efficiency throughout the entire blood transfusion process.